Lab Notes: Stroke Recovery Loves Company

(MedPage Today) — Topping this week’s Lab Notes, mice showed more extensive neuron loss when they were housed alone after induced strokes, suggesting that lack of companionship may interfere with stroke recovery.

|

Ben Venue Plant Trouble Hits One More Onco Drug

(MedPage Today) — Manufacturing problems at Bedford Laboratories’ now-closed Ben Venue manufacturing plant have forced the recall of another important cancer drug, cytarabine.

|

Loreck Homes President and Staff Will Ride Together to Help Conquer Cancer

Loreck Homes to Participate in the Enbridge Ride to Conquer Cancer.

|

News: All Papers are Professionally Copy Edited

All papers published in Libertas journals benefit from our professional copy editing service prior to publication.As part of our production quality control process, we check papers for a wide range of deficiencies prior to publication.&nbsp…

|

News: Breast Cancer: Basic and Clinical Research Call for Papers

|

News: Pubmed and Open Access Visibility in Breast Cancer: Basic and Clinical Research

Articles published in open access journals like Breast Cancer: Basic and Clinical Research have been shown to receive more citations than articles published in restricted access journals.A recent review of the studies on open access citatio…

|

Oral Nutrition Supplements Give Little Help to Cancer Patients (CME/CE)

(MedPage Today) — Malnourished cancer patients had some improvement in quality of life but did not live longer when they received oral nutrition supplements, a meta-analysis showed.

|

Methotrexate Shortage Eases

(MedPage Today) — Fresh supplies of methotrexate are slated for release this month, relieving a serious shortage of the important oncology and rheumatology drug, according to the FDA.

|

Novel Heparin Fights Clots for Cancer Patients (CME/CE)

(MedPage Today) — A novel heparin anticoagulant cuts down on venous thromboembolism during chemotherapy without raising bleeding risk, clinical trial results showed.

|

Amyloidosis Responds to Myeloma Therapy (CME/CE)

(MedPage Today) — Two-thirds of patients with amyloid light-chain amyloidosis remained alive without progression two years after treatment with a regimen developed for multiple myeloma, results of a small clinical trial showed.

|